Diabetes Prevention Program Outcomes Study (DPPOS) Continuation

September 2019 Council

Lead Division/Office


Point(s) of Contact

Barbara Linder, M.D., Ph.D.

Executive Summary

The Diabetes Prevention Program Outcomes Study (DPPOS) is the longitudinal follow-up of the cohort that participated in the Diabetes Prevention Program (DPP). DPP established the efficacy of intensive lifestyle modification or metformin in decreasing incident type 2 diabetes in individuals at high risk for diabetes. These results along with work demonstrating cost-effectiveness of the intensive lifestyle intervention led to the creation of the National DPP that is covered by many private insurers and Medicare. At the end of DPP, participants were offered a modified lifestyle invention and the metformin group was provided open label treatment with metformin. Since 2002, participants have been followed in DPPOS to assess the longer-term effects of the original DPP interventions on multiple outcomes, and to document the clinical course of incident diabetes. The study also provides the opportunity to study aging-associated co-morbidities, including cognition, physical functioning/frailty, and multi-morbidity. The current phase is examining if metformin decreases incident cancer. Since the data are not yet available, it is premature to determine if long-term follow-up should be continued. Therefore, we propose to continue follow-up for one year. During this time, the study group will examine the data and develop a proposal for longer term follow-up of the cohort; this continuation will also allow the collaborating ICs time to determine the scientific importance of the proposal.